Spain not immune to world financial crisis

22 December 2008

Humberto Arnes, the president of Spain's research-based drugmakers' association, Farmaindustria, has stated that the country's pharmaceutical industry is not immune to the world financial crisis. He added that, out of a 40,000 global reduction in the work force, Spanish drug firms had cut back their head count by about 700 in recent months.

The news comes as IMS Health reports a slow down across the leading European markets for retail pharmacy sales (see page 17). Despite this, Spain's performance in the 12 months to October 2008 indicated a 5% increase to $15.5 billion. With a substantially smaller population than the UK, where spending is falling, according to IMS data, Spain could overtake the UK to become Europe's fourth largest prescription medicines market, behind Germany, France and Italy, at some point during 2009.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight